biostudies-literatureUnknown9(2)Unglaub JM<h4>Abstract</h4>The B-cell lymphoma 2 inhibitor venetoclax (VEN) in combination with hypomethylating agents has been approved for first-line treatment of patients with acute myeloid leukemia (AML) ineligible for intensive treatment. VEN-containing treatment strategies may also be effective in relapsed/refractory (R/R) AML; however, comparative studies with conventional therapies for fit patients as a bridge-to-transplant strategy are limited. Using propensity score matching (PSM), we compared 37 patients with R/R AML, who received VEN-based salvage therapy as bridge to allogeneic hematopoietic stem cell transplantation (allo-HCT), with 90 patients from the German Study Alliance Leukemia AML registry, who were treated with non-VEN-containing salvage therapy according to their treating physBlood advances375-385https://www.ebi.ac.uk/biostudies/studies/S-EPMC11787451biostudies-literatureVenetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML.PMC11787451Kraus SSauer TEinsele HPabst CDreger PRenders SBornhauser MKrause SWKauer JZukunft SMiddeke JMMuller-Tidow CKramer MLuft TUnglaub JMSchlenk RFRollig CSchliemann CKatelari EfalseVenetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML.<h4>Abstract</h4>The B-cell lymphoma 2 inhibitor venetoclax (VEN) in combination with hypomethylating agents has been approved for first-line treatment of patients with acute myeloid leukemia (AML) ineligible for intensive treatment. VEN-containing treatment strategies may also be effective in relapsed/refractory (R/R) AML; however, comparative studies with conventional therapies for fit patients as a bridge-to-transplant strategy are limited. Using propensity score matching (PSM), we compared 37 patients with R/R AML, who received VEN-based salvage therapy as bridge to allogeneic hematopoietic stem cell transplantation (allo-HCT), with 90 patients from the German Study Alliance Leukemia AML registry, who were treated with non-VEN-containing salvage therapy according to their treating phys2025-01-01T00:00:00Z2025 Jan2026-06-01T10:26:18.728Z2025-04-04T13:11:30.696ZS-EPMC117874513929308110.1182/bloodadvances.2024013086